MX2022006221A - Síntesis de oligonucleótidos de tipo 3'- arn. - Google Patents

Síntesis de oligonucleótidos de tipo 3'- arn.

Info

Publication number
MX2022006221A
MX2022006221A MX2022006221A MX2022006221A MX2022006221A MX 2022006221 A MX2022006221 A MX 2022006221A MX 2022006221 A MX2022006221 A MX 2022006221A MX 2022006221 A MX2022006221 A MX 2022006221A MX 2022006221 A MX2022006221 A MX 2022006221A
Authority
MX
Mexico
Prior art keywords
synthesis
rna oligonucleotides
oligonucleotides
rna
nucleoside
Prior art date
Application number
MX2022006221A
Other languages
English (en)
Inventor
Mark K Schlegel
Alexander V Kel'in
Shigeo Matsuda
Jayaprakash K Nair
Martin A Maier
Juan C Salinas
John Frederick Briones
Ligang Zhang
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of MX2022006221A publication Critical patent/MX2022006221A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/319Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/30Production chemically synthesised

Abstract

La descripción se refiere a monómeros y métodos para sintetizar oligonucleótidos que comprenden al menos un nucleósido que comprende un grupo 3'-hidroxilo.
MX2022006221A 2019-11-27 2020-11-23 Síntesis de oligonucleótidos de tipo 3'- arn. MX2022006221A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962941153P 2019-11-27 2019-11-27
PCT/US2020/061755 WO2021108291A1 (en) 2019-11-27 2020-11-23 Synthesis of 3'-rna oligonucleotides

Publications (1)

Publication Number Publication Date
MX2022006221A true MX2022006221A (es) 2022-08-10

Family

ID=76129612

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006221A MX2022006221A (es) 2019-11-27 2020-11-23 Síntesis de oligonucleótidos de tipo 3'- arn.

Country Status (10)

Country Link
US (1) US20230021879A1 (es)
EP (1) EP4065715A4 (es)
JP (1) JP2023503985A (es)
KR (1) KR20220107246A (es)
CN (1) CN115038790A (es)
AU (1) AU2020391116A1 (es)
CA (1) CA3162717A1 (es)
IL (1) IL293327A (es)
MX (1) MX2022006221A (es)
WO (1) WO2021108291A1 (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4924624A (en) * 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
CA2140428C (en) * 1992-07-23 2003-07-08 Daniel Peter Claude Mcgee Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof
US6649750B1 (en) * 2000-01-05 2003-11-18 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotide compounds
JP2004522695A (ja) * 2000-09-01 2004-07-29 サーナ・セラピューティクス・インコーポレイテッド ヌクレオシド,ヌクレオシド誘導体および非ヌクレオシド誘導体を合成する方法
US7211654B2 (en) * 2001-03-14 2007-05-01 Regents Of The University Of Michigan Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports
AU2002351077A1 (en) * 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
CN100484949C (zh) * 2005-07-18 2009-05-06 张必良 用于rna寡核苷酸合成中的核苷亚磷酰胺及其合成方法
US8911948B2 (en) * 2008-04-30 2014-12-16 Integrated Dna Technologies, Inc. RNase H-based assays utilizing modified RNA monomers
US8309707B2 (en) * 2008-09-06 2012-11-13 Chemgenes Corporation RNA synthesis-phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end
US8541569B2 (en) * 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
US9802975B2 (en) * 2014-06-10 2017-10-31 Agilent Technologies, Inc. Protecting groups for “Z nucleotide” and methods thereof
EP3455232B1 (en) * 2016-05-12 2020-05-06 Roche Innovation Center Copenhagen A/S Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
JP2019525916A (ja) * 2016-07-27 2019-09-12 ロシュ イノベーション センター コペンハーゲン エーエス 5’s−lnaヌクレオチドおよびオリゴヌクレオチド

Also Published As

Publication number Publication date
JP2023503985A (ja) 2023-02-01
IL293327A (en) 2022-07-01
KR20220107246A (ko) 2022-08-02
CA3162717A1 (en) 2021-06-03
EP4065715A4 (en) 2024-04-10
EP4065715A1 (en) 2022-10-05
US20230021879A1 (en) 2023-01-26
AU2020391116A1 (en) 2022-07-14
WO2021108291A1 (en) 2021-06-03
CN115038790A (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
MX2022004101A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
NZ754731A (en) Azolopyrimidine for the treatment of cancer-related disorders
CY1124306T1 (el) Συνθεσεις και μεθοδοι για τη συνθεση 5´-καλυμμενων rna
MX2020013454A (es) Nucleósidos y nucleótidos con grupos de bloqueo 3'-hidroxi y su uso en métodos de secuenciación de polinucleótidos.
MX2020002183A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos.
MX2019014914A (es) Sintesis de 3'-desoxiadenosina-5'-0-[fenil(benciloxi-l-alaninil)]f osfato (nuc-7738).
MX2020001903A (es) Novedoso polipeptido y procedimiento de produccion de imp mediante el uso del mismo.
SG10201804571TA (en) Substituted nucleosides, nucleotides and analogs thereof
PH12015502799A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12014501436A1 (en) Substituted nucleosides, nucleotides and analogs thereof
MX2017008184A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
SG10201804835VA (en) Substituted nucleosides, nucleotides and analogs thereof
NZ607996A (en) Substituted nucleotide analogs
EP3820473A4 (en) ENZYMATIC SYNTHESIS OF 4'-ETHINYL NUCLEOSIDE ANALOGUES
MY198880A (en) Phosphoramidate nucleoside derivatives as anticancer agents
MX2009011255A (es) Proceso para preparar capecitabina.
AU2018332216B2 (en) Galnac derivatives
MX2015001310A (es) Sintesis de ribonucleosidos deuterados, fosforamiditas n-protegidos, y oligonucleotidos.
MX2020010802A (es) Moleculas inhibidoras de acidos nucleicos de caracter bicatenario modificadas con nucleotidos que aumentan la tm.
CR20240074A (es) Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y métodos de uso
MX2017012598A (es) Composicion y proceso para moldear o modificar la forma del cabello.
MX2022006221A (es) Síntesis de oligonucleótidos de tipo 3'- arn.
WO2021099832A3 (en) Adenosine receptor antagonist compounds
WO2021032777A8 (en) Oligonucleotide conjugate compositions and methods of use
EP3933044A4 (en) CONVENIENT ENZYME SYNTHESIS OF 3', 3'-CGAMP